CA15-3 is a useful serum tumor marker for diagnostic integration of hybrid positron emission tomography with integrated computed tomography during follow-up of breast cancer patients

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Incoronato, Mariarosaria ^a   Mirabelli, Peppino ^a   Catalano, Onofrio ^a   Aiello, Marco ^a   Parente, Chiara ^a   Soricelli, Andrea ^a,b   Nicolai, Emanuele ^a  

^a IRCCS SDN   (Italy)

^b UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

Author keywords

Breast cancer; CA15 3; Computed tomography; Positron emission tomography; Serum biomarkers

Indexed keywords

AROMATASE INHIBITOR; CA 15-3 ANTIGEN; FLUORODEOXYGLUCOSE F 18; TAMOXIFEN; TRASTUZUMAB; BIOLOGICAL MARKER; MUC1 PROTEIN, HUMAN; MUCIN 1;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HUMAN; MALE; MEDICAL HISTORY; MEDICAL RECORD; OUTCOME ASSESSMENT; PET SCANNER; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; VERY ELDERLY; AREA UNDER THE CURVE; BLOOD; BREAST NEOPLASMS; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; EVALUATION STUDY; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; RADIOGRAPHY; RISK FACTOR; SCINTISCANNING; SECONDARY; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BIOLOGICAL MARKERS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; MUCIN-1; MULTIMODAL IMAGING; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; UP-REGULATION;

EID: 84901603980     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-356     Document Type: Article

References (27)

1. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013, 132:1133-1145. 10.1002/ijc.27711, 22752881.
2. Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E, . on behalf of the ESMO Guidelines Working Group Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol 2012, 23(Suppl 7):vii11-vii19. on behalf of the ESMO Guidelines Working Group.
3. Gil-Rendo A, Martínez-Regueira F, Zornoza G, García-Velloso MJ, Beorlegui C, Rodriguez-Spiteri N. Association between [18 F] fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg. 2009, 96:166-170. 10.1002/bjs.6459, 19160365.
4. Groheux D, Giacchetti S, Moretti JL, Porcher R, Espié M, Lehmann-Che J, de Roquancourt A, Hamy AS, Cuvier C, Vercellino L, Hindié E. Correlation of high 18 F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging 2011, 38:426-435. 10.1007/s00259-010-1640-9, 21057787.
5. Wang Y, Zhang C, Liu J, Huang G. Is 18 F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis. Breast Cancer Res Treat 2012, 131:357-369. 10.1007/s10549-011-1780-z, 21960111.
6. Evangelista L, Cervino AR, Ghiotto C, Al-Nahhas A, Rubello D, Muzzio PC. Tumor marker-guided PET in breast cancer patients-a recipe for a perfect wedding: a systematic literature review and meta-analysis. Clin Nucl Med 2012, 37:467-474. 10.1097/RLU.0b013e31824850b0, 22475896.
7. Grassetto G, Fornasiero A, Otello D, Bonciarelli G, Rossi E, Nashimben O, Minicozzi AM, Crepaldi G, Pasini F, Facci E, Mandoliti G, Marzola MC, Al-Nahhas A, Rubello D. 18 F-FDG-PETCT in patients with breast cancer and rising CA15-3 with negative conventional imaging: a multicentre study. Eur J Radiol 2011, 80:828-833. 10.1016/j.ejrad.2010.04.029, 20547020.
8. Suárez M, Pérez-Castejón MJ, Jiménez A, Domper M, Ruiz G, Montz R, Carreras JL. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumour markers. Q J Nucl Med 2002, 46:113-121.
9. Mirabelli P, Incoronato M. Usefulness of traditional serum biomarkers for management of breast cancer patients. Biomed Res Int 2013, doi:10.1155/2013/68564.
10. Haug AR, Schmidt GP, Klingenstein A, Heinemann V, Stieber P, Priebe M, la Fougère C, Becker C, Hahn K, Tiling R. F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the follow-up of breast cancer with elevated levels of tumour markers. J Comput Assist Tomogr 2007, 31:629-634. 10.1097/01.rct.0000284394.83696.42, 17882045.
11. Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, Goike H, Lamerz R, Nap M, Sölétormos G, Stieber P. Tumor markers in breast cancer - European group on tumour markers recommendations. Tumor Biol 2005, 26:281-293.
12. European group on tumour marker. EGTM guideline for breast cancer. Available from: http://www.egtm.eu/professionals/breast_cancer. Accessed 2 April 2013.
13. Erdi YE, Mawlawi O, Larson SM, Imbriaco M, Yeung H, Finn R, Humm JL. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer 1997, 80:2505-2509. 10.1002/(SICI)1097-0142(19971215)80:12+<2505::AID-CNCR24>3.0.CO;2-F, 9406703.
14. Evangelista L, Baretta Z, Vinante L, Cervino AR, Gregianin M, Ghiotto C, Saladini G, Sotti G. Tumour markers and FDG PETCT for prediction of disease relapse in patients with breast cancer. Eur J Nucl Med Mol Imaging 2011, 38:293-301. 10.1007/s00259-010-1626-7, 20882280.
15. McMahon CJ, Crowley V, McCarroll N, Dunne R, Keogan MT. Elevated tumour marker: an indication for imaging?. Ann Clin Biochem 2010, 47(4):327-330. 10.1258/acb.2010.009235, 20511377.
16. Duffy MJ, Evoy D, McDermott EW. CA15-3: uses and limitation as a biomarker for breast cancer. Clin Chim Acta 2010, 411:1869-1874. 10.1016/j.cca.2010.08.039, 20816948.
17. Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, Hantel A, Henry NL, Muss HB, Smith TJ, Vogel VG, Wolff AC, Somerfield MR, Davidson NE. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013, 31(7):961-965. 10.1200/JCO.2012.45.9859, 23129741.
18. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, Babaian R, Bast RC, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih IM, Sibley P, Sölétormos G, Stephan C, Sokoll L, Hoffman BR, Diamandis EP. National Academy of Clinical Biochemistry: National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008, 54(12):e11-e79. doi:10.1373/clinchem.2008.105601, 10.1373/clinchem.2008.105601, 19042984.
19. Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, Oyen WJ, Kotzerke J, Hoekstra OS, Pruim J, Marsden PK, Tatsch K, Hoekstra CJ, Visser EP, Arends B, Verzijlbergen FJ, Zijlstra JM, Comans EF, Lammertsma AA, Paans AM, Willemsen AT, Beyer T, Bockisch A, Schaefer-Prokop C, Delbeke D, Baum RP, Chiti A, Krause BJ. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010, 37:181-200. 10.1007/s00259-009-1297-4, 2791475, 19915839.
20. Champion L, Brain E, Giraudet AL, Le Stanc E, Wartski M, Edeline V, Madar O, Bellet D, Pecking A, Alberini JL. Breast cancer recurrence diagnosis suspected on tumour marker rising: value of whole-body 18FDG-PET/CT imaging and impact on patient management. Cancer 2011, 117:1621-1629. 10.1002/cncr.25727, 21472709.
21. Filippi V, Malamitsi J, Vlachou F, Laspas F, Georgiou E, Prassopoulos V, Andreou J. The impact of FDG-PET/CT on the management of breast cancer patients with elevated tumor markers and negative or equivocal conventional imaging modalities. Nucl Med Commun 2011, 32:85-90. 10.1097/MNM.0b013e328341c898, 21127445.
22. Evangelista L, Baretta Z, Vinante L, Cervino AR, Gregianin M, Ghiotto C, Bozza F, Saladini G. Could the serial determination of Ca15.3 serum improve the diagnostic accuracy of PET/CT? Results from small population with previous breast cancer. Ann Nucl Med 2011, 25:469-477. 10.1007/s12149-011-0488-9, 21476056.
23. Katayama T, Kubota K, Machida Y, Toriihara A, Shibuya H. Evaluation of sequential FDG-PET/CT for monitoring bone metastasis of breast cancer during therapy: correlation between morphological and metabolic changes with tumor markers. Ann Nucl Med 2012, 26:426-435.
24. Sölétormos G, Nielsen D, Schiøler V, Mouridsen H, Dombernowsky P. Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA. Eur J Cancer. 2004, 40(4):481-486. 10.1016/j.ejca.2003.10.015, 14962712.
25. Laessig D, Nagel D, Heinemann V, Untch M, Kahlert S, Bauerfeind I, Stieber P, Siggelkow W, Rath W, Buell U, Zimny M. FDG PET and tumour markers in the diagnosis of recurrent and metastatic breast cancer. Eur J Nucl Med Mol Imaging 2004, 31(Suppl 1):S118-S124.
26. Mariani L, Miceli R, Michilin S, Gion M. Serial determination of CEA and CA 15.3 in breast cancer follow-up: an assessment of their diagnostic accuracy for the detection of tumour recurrences. Biomarkers 2009, 14:130-136. 10.1080/13547500902770090, 19330591.
27. Nicolini A, Carpi A, Ferrari P, Anselmi L, Spinelli C, Conte M, Miccoli P. The role of tumour markers in improving the accuracy of conventional chest X-ray and liver echography in the post-operative detection of thoracic and liver mestases from breast cancer. Br J Cancer 2000, 83:1412-1417. 10.1054/bjoc.2000.1477, 2363419, 11076646.